Upgrade to SI Premium - Free Trial

Pre-Open Stock Movers 04/20: AlloVir, I-Mab Biopharma Gain; Netflix Plunges (more...)

April 20, 2022 9:23 AM

Pre-Open Stock Movers:

Netflix (NASDAQ: NFLX) 28% LOWER; Q1 global streaming subscribers fell 200k versus an expected gain of 2.5 million. Q1 EPS was $3.53, versus the consensus of $2.90. Revenue was $7.87 billion versus the consensus estimate of $7.93 billion. Netflix sees Q2 2022 EPS of $3.00, versus the consensus of $3.01. Netflix sees Q2 2022 revenue of $8.05 billion, versus the consensus of $8.21 billion. The company sees Q2 global streaming paid net additions of -2 million, versus the consensus of 2.4 million.

AlloVir (NASDAQ: ALVR) 25% HIGHER; FDA Grants RMAT Designation for Posoleucel

I-Mab Biopharma (NASDAQ: IMAB) 17% HIGHER; is exploring options including a sale amid takeover interest, Bloomberg reported.

Roku, Inc. (NASDAQ: ROKU) 7% LOWER; falls on Netflix's results, which could be an ominous sign for Roku's results.

The Walt Disney Company (NYSE: DIS) 5% LOWER; falls on Netflix's results, which could be ominous for Disney+ numbers.

Teva (NYSE: TEVA) 4% LOWER; The company and MedinCell announced that the FDA has issued a Complete Response Letter regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia

Spotify (NYSE: SPOT) 4% LOWER; falls on Netflix's results.

Stride Inc. (NYSE: LRN) 4% HIGHER; reported Q3 EPS of $1.02, versus the consensus of $0.84. Revenue was $421.7 million versus the consensus estimate of $411.12 million. Stride Inc. sees FY2022 revenue of $1.645-1.66 billion, versus the consensus of $1.63 billion

Anthem (NYSE: ANTM) 3% HIGHER; posted Q1 EPS of $8.25, versus the consensus of $7.81. Revenue was $37.9 billion versus the consensus of $37.42 billion. Anthem sees FY2022 EPS of $28.40, versus the consensus of $28.48

IBM (NYSE: IBM) 2% HIGHER; Q1 EPS was reported at $1.40, $0.02 better than the analyst estimate of $1.38. Revenue was $14.2 billion versus the consensus estimate of $13.85 billion. The company sees revenue growth for the year at the high end of its model.

Categories

Special Reports